Apellis Pharmaceuticals I...

NASDAQ: APLS · Real-Time Price · USD
28.65
1.03 (3.73%)
At close: Aug 15, 2025, 12:33 PM

Apellis Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
178.49M 166.8M 212.53M 196.83M 199.69M 172.32M 146.38M 110.4M 94.97M 44.85M 22.66M 22.06M 16.32M 14.38M 60.29M 5.65M 623K n/a
Cost of Revenue
14.07M 34.36M 40.86M 33.56M 23.55M 20.65M 19.91M 22.41M 8.38M 7.81M 2.92M 1.38M 82K 1.25M 5.05M 149K 50M 124.59M
Gross Profit
164.42M 132.44M 171.67M 163.27M 176.14M 151.67M 126.47M 87.99M -9.07M 37.04M 19.74M 20.68M 16.24M 13.13M 55.24M 5.17M -49.38M -124.59M
Operating Income
-33.29M -83.33M -26.16M -47.28M -29.44M -62.09M -84.52M -148.3M -120.44M -175.08M -164.05M -152.94M -148.62M -129M -89.4M -128M -194.29M -124.59M
Interest Income
2.61M 2.66M 3.4M 2.89M 3.18M 3.3M 4.55M 4.99M 6M 5.39M 4.58M 2.81M 1.43M 98K 37K 144K 104K 134K
Pretax Income
-41.69M -91.88M -36.07M -56.85M -37.54M -66.25M -87.15M -140M -121.84M -177.5M -167.46M -190.82M -155.49M -137.73M -147.58M -195.57M -219.19M -183.66M
Net Income
-42.15M -92.22M -36.35M -57.45M -37.66M -66.42M -88.58M -140.24M -122.04M -177.78M -165.99M -191.27M -155.98M -138.94M -147.93M -195.57M -219.19M -183.66M
Selling & General & Admin
130.69M 129.34M 121.48M 121.98M 127.63M 129.06M 141.7M 145.65M 111.37M 102.09M 84.37M 78.41M 63.2M 51.19M 41.46M 45.76M 48.97M 40.58M
Research & Development
67.02M 86.42M 76.35M 88.57M 77.95M 84.7M 69.28M 79.42M 95.66M 110.03M 99.42M 95.21M 101.66M 90.94M 108.18M 87.73M 145.94M 84.01M
Other Expenses
n/a n/a n/a n/a 24K -499K 219K -603K -63K -277K -246K 99K 149K -289K -4K -117K -61K 1.54M
Operating Expenses
197.71M 215.76M 197.84M 210.55M 205.58M 213.76M 210.98M 225.07M 207.03M 212.12M 183.79M 173.61M 164.86M 142.13M 144.64M 133.5M 144.91M 124.59M
Interest Expense
11.15M 11.05M 11.53M 12.53M 9.36M 6.97M 7.4M 7.31M 7.34M 7.53M 7.74M 7.9M 8.45M 8.54M 3.02M 2.28M 3.77M 4.17M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
211.78M 250.13M 238.69M 244.11M 229.13M 234.41M 230.9M 247.48M 215.41M 219.93M 186.72M 174.99M 164.95M 143.38M 149.69M 133.65M 194.91M 124.59M
Income Tax Expense
466K 341K 286K 592K 114K 170K 1.42M 233K 194K 282K -1.47M 446K 486K 1.21M 352K n/a n/a n/a
Shares Outstanding (Basic)
126.02M 125.45M 123.9M 123.9M 123.9M 122.96M 121.23M 120.29M 119.32M 113.87M 110.63M 109.13M 106.63M 97.84M 85.66M 85.66M 80.65M 79.22M
Shares Outstanding (Diluted)
126.02M 125.45M 123.9M 123.9M 123.9M 122.96M 121.23M 120.29M 119.32M 113.87M 110.63M 109.13M 106.63M 98.07M 85.66M 85.66M 80.65M 79.22M
EPS (Basic)
-0.33 -0.74 -0.29 -0.46 -0.3 -0.54 -0.73 -1.17 -1.02 -1.56 -1.5 -1.75 -1.46 -1.42 -1.73 -2.28 -2.72 -2.32
EPS (Diluted)
-0.33 -0.74 -0.29 -0.46 -0.3 -0.54 -0.73 -1.17 -1.02 -1.56 -1.5 -1.75 -1.46 -1.42 -1.73 -2.28 -2.72 -2.32
EBITDA
-30.09M -80.39M -24.09M -43.86M -27.73M -58.84M -79.26M -132.29M -114.09M -169.57M -159.3M -182.56M -146.7M -128.83M -144.19M -193.01M -214.98M -179.09M
EBIT
-30.53M -80.83M -24.53M -44.32M -28.18M -59.29M -79.75M -132.69M -114.5M -169.97M -159.72M -182.92M -147.04M -129.19M -144.72M -193.29M -215.42M -179.48M
Depreciation & Amortization
446K 446K 447K 457K 449K 444K 490K 405K 410K 399K 428K 357K 342K 360K 376K 274K 448K 394K